title: Sofosbuvir as backbone of interferon free treatments.
abstract: Sofosbuvir is the first-in-class NS5B nucleotide analogues to be launched for hepatitis C virus (HCV) treatment. Its viral potency, pangenotypic activity and high barrier to resistance make it the ideal candidate to become a backbone for several IFN-free regimens. Recent data demonstrated that sofosbuvir either with ribavirin alone or in combination with other direct-acting antivirals (DAAs) as daclatasvir, ledipasvir or simeprevir are able to cure HCV in at least 90% or over of patients. Treatment experienced genotype 3 population may remain the most difficult to treat population, but ongoing DAA combination studies will help to fill this gap. Safety profile of sofosbuvir or combination with other DAAs is good. Resistance to sofosbuvir did not appear as a significant issue. The rationale for using this class of drug and the available clinical data are reviewed.
authors.affiliation: Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseilles, France. Electronic address: mbourliere@hopital-saint-joseph.fr.
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
authors.affiliation: Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseilles, France.
authors.forename: Valèrie
authors.initials: V
authors.lastname: Oules
authors.affiliation: Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseilles, France.
authors.forename: Christelle
authors.initials: C
authors.lastname: Ansaldi
authors.affiliation: Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseilles, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Adhoute
authors.affiliation: Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseilles, France.
authors.forename: Paul
authors.initials: P
authors.lastname: Castellani
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy*; D019701:Hepatitis D, Chronic / Q000188:drug therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D000069474:Sofosbuvir; D016896:Treatment Outcome; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D014542:Uridine Monophosphate; D000069474:Sofosbuvir
keywords: DAAs; Daclatasvir; HCV; IFN-free; NS5B nucleotide inhibitors; Ribavirin; Simeprevir; Sofosbuvir